Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“A pioneer in APS testing, Prof. Pier Luigi Meroni delivered a powerful message at ISTH 2026 in Paris yesterday: what do we really target with our aPL assays?
His update on harmonizing ELISA and non‑ELISA antiphospholipid antibody tests with new commutable reference material for anti‑β2GPI and aCL IgG showed that standardization of units is possible—but that variability from assay design and antibody heterogeneity remains.
For me, the key takeaway was a clear shift from ‘any aPL positive’ towards biologically meaningful β2GPI‑dependent specificities and domain reactivity, which should drive future APS risk stratification, classification, and guidelines.
But how ready are our routine laboratories to embrace this more targeted, domain‑focused approach to APS testing?”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Oct 18, 2026, 08:02Neda Ashayeri: Global Perspectives on Hemophilia and Rare Bleeding Disorders in Abu Dhabi
-
Oct 18, 2026, 07:55Anu Thomas: A Stepwise Laboratory Approach to Positive IAT and Pretransfusion Compatibility
-
Oct 18, 2026, 07:49Matthew Hazell: Molecular Matching and the Future of Transfusion Practice
-
Oct 18, 2026, 07:05Behnood Bikdeli: Vasculearn Network Highlights Expert Perspectives on PE Risk Stratification and Advanced Therapies
-
Oct 18, 2026, 06:27Gregory Makris: NEJM Study Supports Earlier Catheter-Directed Intervention in Intermediate-High–Risk PE
-
Oct 18, 2026, 06:26Danny Hsu: BLOOD 2026 Return to Aotearoa
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH